Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks Shag, he looks like Edward James Olmos.
i believe his info is accurate but outdated...the original broker dropped them months ago and that was the reason for the holdup.
BOCX mentioned again on a blog:
hxxp://pmhj.blogspot.com/2005/08/more-nss-background-information.html
Headache the content on google and yahoo is so stale compared to Technorati, albeit much more comprehensive. With Yahoo/Google the spiders only update periodically so it's like looking at delayed quotes rather than real-time.
Headache: I search Technorati multiple times a day for mentions of BOCX and other sites I own. That is how I found the link. Technorati is a great site because it gives you real-time "chatter" on the net. I also search yahoo new (news.yahoo.com) multiple times a day and sometimes I find wierd things I don't even post. Like for instance the former figurehead CEO of biocurex was appointed to run some other company.
I just searched blogspot and found BOCX mentioned on some blog named Q Trader, anyone ever heard of it?
qtrader.blogspot.com
-- very positive. I wonder what they had to say in their "July Roundup" when they supposedly highlighted the stock. Maybe it's related to Aurelius since they highlighted the stock during July too? Then again so did Green Baron...it might be related to one of the two or maybe the guy that runs it gets some of his leads from Aurelius/GB.
and the bid continues EOM
mysscat I recently posted a list of abbott's cancer test menu...there are only 9 of them. So there is no way we're getting lost on the test menu (if you make it there) -- we will be in rarified air. There are hundreds of little specialty tests for the ARCHITECT system across many different types of diseases, but the cancer marker menu is TINY.
headache: yup, but recall during the last accumulation period the stock too breathers too.
Wierd that we haven't traded a share yet...LT re ragingbull I was having problems recently but not anymore.
Does anyone else show $1.29 x $1.31 right now? I know this doesn't trade pre-market but I have a bid/ask posted on my data provider.
longterm: no doubt about it after the recent filing.
i agree LT. it's been so long that I forgot about the pink sheets issue, but come to think about it we should be getting off soon.
LT you may be right
Rob I'm starting to join your camp, as the action is reminding me very much of the action before our last big pop. But I remain cautious due to the announced placement and recent hiring of the tout firms. Of course there is PLENTY of pending news flow though that could hit any time.
12k block just brought us to a new high of $1.28....I'm starting to think the rob camp might be on target.
Are you guys seeing this volume? We just got three 10k blocks and a 40k block. Already traded 140k so early in the day? Hmmm...
Rise and shine people it's time to see if this price/volume trend continues.
An indemnification clause is standard in many LLC operating agreements and Sub-S/C/etc corporate bylaws. I believe the disclosure in the filing is to make investors aware that any such indemnification clause in their bylaws would be overridden by the Securities Act and other investor protection laws.
We definitely have a bid here, I wonder if anything will come of it.
longterm that would be smart of the company...we need to sell shares closer to that $2.50 max price.
gaboy they are working on "integrating" the RECAF assay into a format usable by Abbott's ARCHITECT system. At least in my case, that is what the company said would take 4 - 6 months. After they integrate onto ARCHITECT, things should get interesting.
At this point I wouldn't trust ANYBODY'S projections of time frames because at this point nobody knows Abbott's regulatory & commercial strategies. There are a number of different scenarios.
I like the volume, too, but the recently announced placement could adversely affect us in the near-term. I'm not getting too excited yet for that reason..JMHO.
Even the time frames that aurelius, green baron, small cap net, and THE COMPANY THEMSELVES are throwing out there (12 - 24 months, etc, etc) should all be taken with a grain of salt. According to management at BOCX, they do not even know what regulatory strategy or initial indication Abbott will pursue. Nobody has any idea what type of a trial Abbott will do and for long, or if they will even do a formal trial, etc. Everything is speculation at this point.
cannon: in reality everybody is just pulling meaningless numbers out of their a**. pure jerk-off excercise.
gaboy, if aurelius is right and wittenberg is right about fixed op ex going forward, we're looking at a few dollars a share EPS which would mean a $30 - $50 share price. But I'm not taking any of these projections seriously for the time being. We need more data before we can determine what RECAF's role and success in the market will be.
gaboy, those deals are for cancer-specific markers. RECAF is a different animal...it will be used in CONJUNCTION with cancer-specific markers. It will not replace or compete with the cancer-specific markers.
Notice Abbott Diagnostics only has 9 cancer reagents available between all of their testing platforms, and only 10 collaborations with other companies. So much for the argument that RECAF will just become a blip on the ARCHITECT test menu, or that BOCX is just a blip amongst Abbott's many partners. I can't even believe my ears when I hear things like "ALL we have is a deal with Abbott." That is MAJOR stuff, and the majority of companies in our industry would kill for a deal with Abbott.
The deal puts us in rarified air -- the fact that we made it through their screening process gives us an extremely high probability of "making it". Wittenberg reinforced that point on the latest interview FOR A REASON.
Abbott Diagnostics cancer test menu:
http://abbottdiagnostics.com/Reagents_Tests/default.cfm?testcat_id=3&path=1
Abbott Diagnostics collaborations:
http://abbottdiagnostics.com/About_Us/alliances.cfm
Ar-bit-rage = Gooodman...WELCOME ABOARD GLAD TO HAVE YOU.
Headache I don't think it's a big deal either...just comical to see how very far from slick these guys are. The good news is that bad investor relations can be fixed, but bad technology cannot. I think we have the more important of the two covered.
Wow arbitrage you're truly an amateur aren't you...
1) Whispering Oaks did not buy the rights to RECAF...Moro has owned the IP since day 1 and did a reverse merger into the Whispering Oaks shell.
2) You want a link to BOCX's filings? Ever heard of EdgarOnline buddy? So let me get this straight, you are making strong statements about BOCX without even having read the filings? I wish you the best of luck in relying on message boards for your due diligence.
Please get a clue as quick as possible.
gaboy like I've said smallcapnetwork is better than nothing but they are beyond mickey mouse. if BOCX had the CASH to hire a top investor and media relations firms with contacts -- Aurelius doesn't exactly qualify -- we could get this story some real press and exposure very fast. also, besides IR and MR if we had cash we could hire firms like euro RSCG to bring in more collaborations, quest diagnostics or another turn-key clinical trial provider to run some larger trials for us, etc. and NO, issuing penny stock equity will not get us in the door anywhere except of course for outfits like smallcapnetwork and greenbaron.
bottom line is it's easy to come up with a wish list for things we could do if we had cash, but until we actually do get some cash we are going to move at a snail's pace and remain in little league. thus I applaud the recently filed 8-k, even if we get diluted. my only hope is that they don't discount the s**t out of the common they sell like they have in the past...but then again who would buy this stock direct and in quantity without a heavy discount? beats me.
lol smallcap network is such a silly racket...better than nothing though.
Even if those reports were not paid for, they would still have no effect because they are mickey mouse caliber with a mickey mouse subscriber base. We need 1) the momentum crowd, or 2) institutional investors to get this thing moving.
The momentum crowd is hard to predict...they have been in this stock before and will be back again. But they need a new catalyst in the form of take your breathe away news. CAFE is the best recent example -- they announced plans to pilot their product at 10 wal-marts and the stock shot up from a few dollars to $16 trading many many times it's float. Incidentally, the SEC stepped in and did the same thing they did to us when the momo crowd got a hold of us -- they halted the stock to look into the possibility that the P.R was misleading. I wouldn't be surprised if the SEC doesn't ever charge the company with anything yet causes severe damage to their share price and credibility (as in our case).
The institutional crowd is much easier to predict...they will take positions when the following critera are met:
1) we trade on a real exchange (OTC-BB doesn't count...it's got to be AMEX or NASDAQ)
2) we publish official data that is comparable to our preliminary results
3) we have some cash on our balance sheet
dakota thanks for the names...if you're also trading real stocks I don't know how you could possibly resort to scalping BOCX unless you're doing it on a more intermediate term basis. Intra-day give me a break...like I said 5 to 10 cent spread ON EACH LEG & no liquidity so you'll move the market around. Unless you're a market maker odds are heavily against you unless you're position trading long or intermediate term.
LOL look how sloppy these guys are, I love it! At 9:20 pm, an hour after the news release came out, they put this on the wire:
CORRECTING AND REPLACING -- BioCurex Research Report Available
Friday July 22, 9:20 pm ET
RICHMOND, British Columbia, July 22, 2005 (PRIMEZONE) -- In a release sent earlier today under the same headline, please note the addition of a sentence to the first paragraph, following the first sentence: ``The report strictly represents the views of the analyst concerning Biocurex.'' The full corrected release follows:
(it then goes on to give the corrected version)
NEWS:
Press Release Source: BioCurex, Inc.
BioCurex Research Report Available
Friday July 22, 8:15 pm ET
RICHMOND, British Columbia, July 22, 2005 (PRIMEZONE) -- BioCurex Inc. (Other OTC:BOCX.PK - News) wishes to advise its shareholders of the availability of an independent research report on the Company prepared by Emergent Growth Analytics Research. The report is available at http://www.smallcapnetwork.net/bocx_signup.html concerning BioCurex. The information may be of interest to the shareholders of BioCurex and the link to the report is provided for their benefit.
ADVERTISEMENT
BioCurex is advancing in its corporate goals and will provide the appropriate updates. The Company is pleased to note that it is receiving increasing attention for its patented/proprietary technology for the detection of many types of cancer with a basic blood test.
BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others. Abbott's goal is to further develop this technology, incorporating it into future tests on their ARCHITECT(r) system, for use in cancer diagnosis and monitoring.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To read more about the Company, please visit the News section in our web site (http://www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are ``forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
Contact:
BioCurex, Inc.
Dr. Ricardo Moro
(604) 207-9150
dakota...the "boys at Abbott" (as in management) would not be buying stock in this company. Give me a break. You really think their legal counsel would clear it? NOT A CHANCE IN HELL. Institutions or the mo-mo crowd will move this stock, and neither are anywhere in sight. As far as trading 6k today -- are you talking about intra-day trading BOCX? That's the funniest thing I've ever heard...the market maker asks for a 5 to 10 cent spread on each leg and the ATR has gone down to virtually nothing (ten to 20 cents). Not to mention the non-existant volume. Really man that is off the charts wacky...why wouldn't you trade real momentum stocks? FWIW My plan for next week is the energy sector as volatility will be there in full force...e&p, refinery, and oil service names are all reporting in one big cluster next week. Today we saw volume move away from tech and into energy and that will continue next week. Might want to keep an eye on SII, SWN, RIG, VLO, and the other volatile energy names. Not that the tech rally is over, but next week energy will have the volume and volatility. Based on the HAL and SLB blowout numbers and subsequent runaway breakouts, I think the most bang for buck out of the oils next week is drilling/production/parts as opposed to downstream like refineries/transport, etc. If you only like penny stocks that's fine but keep your energy names on the radar next week.
You got any ideas for next week?
dakota: I say again that this is an off-the-radar, nobody knows it exists yet stock, not a momentum stock.
dakota: news flash, this is not a momentum stock.